Doxorubicin for Breast Cancer: 106 Real Stories

106 stories match breast cancer and doxorubicin. 100 of them mention surgery.

Cancer Stories

A patient, who was diagnosed with Stage I Invasive Ductal CarcinomaBreast Cancer

Stage IIIA HR-positive HER2-negative breast cancer with radiation-induced brachial plexopathy

Patient Info: Anonymized, Female, 50s | Stage I

Biomarkers: HR-positive/HER2-negative breast cancer with pathogenic ATM and PALB2 variants plus an ATM VUS.

Approximately 3.5 years after radiation therapy, there was no evidence of breast cancer recurrence, but severe radiation-induced brachial plexopathy, fibrosis, telangiectasias, and lymphedema-related symptoms required ongoing supportive care.

PubMed Central
OutcomeCancer-Free / NED
TB
Breast Cancer

Triple-negative breast cancer in remission after chemotherapy and pembrolizumab

Patient Info: Anonymized, Female, 50s

Biomarkers: ER-negative; PR-negative; HER2-negative

Triple-negative breast cancer was in remission, with PET-CT showing no new primary or secondary tumors, while pembrolizumab-related adrenal insufficiency required ongoing endocrine management.

PubMed Central
OutcomeCancer-Free / NED
Lauren, who was diagnosed with Invasive Ductal CarcinomaBreast Cancer

Invasive Ductal Carcinoma: Lauren's Survivor Story

Patient Info: Lauren O'Connell, Female

As of September 2024, Lauren had completed lumpectomy, chemotherapy, and 25 rounds of radiation. She described major emotional change and recovery, but no formal NED or cancer-free status was reported.

YouTube — The Patient Story
OutcomeSurvivorship / Completed Treatment
A patient, who was diagnosed with Stage III Breast CancerBreast Cancer

Triple-negative breast cancer: partial response to TAC chemotherapy

Patient Info: Anonymized, Female, 70+ | Stage III

Biomarkers: Triple-negative breast cancer with EGFR positivity and high Ki-67; BRCA1 staining was positive by IHC.

After 1 cycle of TAC chemotherapy, the large ulcerated breast tumor shrank enough for surgery. Radical mastectomy with adjacent flap transfer achieved clear margins and no nodal metastatic cancer; she was recovering at home while awaiting planned postoperative AC-T chemotherapy.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

Triple-negative breast cancer: partial response to immunotherapy combination

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Initial tumor: ER-negative; PR-negative; HER2-negative; Ki-67 >80%

Metastatic Site: left lung, neck lymph nodes, mediastinal lymph nodes

Metastatic triple-negative breast cancer had a partial response after 9 months of pembrolizumab plus MK-4830, with reduced tumor burden, decreased lung and mediastinal metastases, and no new metastatic lesions; immunotherapy continued after prednisone controlled a grade 2 lichenoid eruption.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Stage 4 invasive ductal carcinoma: metastatic disease with bone involvement managed successfully

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER <1%; PR 0%; HER2 score 3+; Ki-67 60%

Metastatic Site: bone (12th thoracic vertebra/T12)

Stage IV HER2-positive breast cancer had improved T12 bone metastasis, major breast-tumor regression on trastuzumab deruxtecan, and pathologic complete response in the breast after mastectomy; durable systemic disease status was not reported.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Invasive Ductal CarcinomaBreast Cancer

Stage 3 breast cancer: pathologic complete response to neoadjuvant chemotherapy

Patient Info: Anonymized, Female, Under 40

Biomarkers: ER-positive, PR-negative, HER2-negative breast cancer with very high Ki-67. MammaPrint high-risk/basal type; hereditary testing negative.

Free of recurrence at last follow-up after neoadjuvant pembrolizumab plus chemotherapy, breast-conserving surgery with RCB-0/pathologic complete response, adjuvant radiation, and adjuvant pembrolizumab.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage II Invasive Ductal CarcinomaBreast Cancer

Stage 2 triple-negative breast cancer: pathologic complete response to chemotherapy

Patient Info: Anonymized, Female, 40s | Stage II

Biomarkers: Triple-negative breast cancer, with pathogenic PALB2 c.1451T>A variant found in blood/buccal/tumor testing.

As of May 2024, more than 1 year after surgery, she was well and free of cancer after neoadjuvant chemotherapy, mastectomy, reconstruction, and preventive adnexectomy.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Breast CancerBreast Cancer

Triple-negative metaplastic breast cancer with complete pathologic response to chemotherapy

Patient Info: Anonymized, Female, 40s

Biomarkers: ER-negative; PR-negative; HER2-negative; Ki-67 <10%; CK-positive; S100-positive; focal vimentin-positive

At 1-year follow-up, there were no signs of recurrence after doxorubicin/cyclophosphamide chemotherapy and modified radical mastectomy with complete pathologic response.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Invasive Lobular CarcinomaBreast Cancer

Invasive lobular breast cancer with isolated scalp metastasis: excision and endocrine therapy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Original breast tumor: ER-positive; PR-positive; scalp metastasis: CK7-positive; ER-positive; GCDFP-15 partially positive

Metastatic Site: scalp/skin

As of April 2024, she had no signs of recurrence in the breast or scalp and no distant metastasis after excision of the isolated scalp metastasis while continuing anastrozole.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

Metastatic hormone receptor-positive breast cancer with paraneoplastic eosinophilic fasciitis

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: ER-positive; PR-positive; eosinophilia during paraneoplastic eosinophilic fasciitis flare

Metastatic Site: pelvis

As of February 2024, paraneoplastic eosinophilic fasciitis had remitted after prednisone plus systemic breast-cancer therapy, and 6-month follow-up showed no further skin recurrence or cancer progression.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage III Breast CancerBreast Cancer

Stage IIIA breast cancer history with benign lipid pneumonia mimicking lung malignancy

Patient Info: Anonymized, Female, 40s | Stage III

Prior Stage IIIA breast cancer treatment was completed; a later suspicious lung lesion proved to be benign lipid pneumonia rather than recurrence or lung cancer, and she was asymptomatic 1 year after lobectomy with continued surveillance for new right-lung changes.

PubMed Central
OutcomeSurvivorship / Completed Treatment
A patient, who was diagnosed with Stage IV Invasive Lobular CarcinomaBreast Cancer

Treatment-Refractory Triple-Negative Breast Cancer Treated With Tumor-Infiltrating Lymphocytes

Patient Info: Anonymized, female, Under 40 | Stage IV

Biomarkers: Germline BRCA1 pathogenic variant; later triple-negative phenotype

Metastatic Site: skin, lungs, bones

Tumor burden briefly decreased after tumor-infiltrating lymphocyte therapy, but she developed severe treatment complications followed by rapid cancer relapse and died about 1 month after the TIL/IL-2 treatment began.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

Adenoid Cystic Breast Cancer Spreads to the Kidney, Lungs, Bone and Spleen

Patient Info: Anonymized, female, 70+ | Stage IV

Biomarkers: Triple-negative

Metastatic Site: kidneys, lungs, spleen, bone, lymph nodes

The cancer progressed from an initial kidney metastasis to widespread disease involving the lungs, spleen, right kidney, lymph nodes, and C4 vertebra. By May 2022 she had worsening cachexia and pain, and best supportive care was recommended.

PubMed Central
OutcomeSetback / Progression
April, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV Triple-Negative Breast Cancer: April's Patient Story

Patient Info: April Donaldson, Female, 40s | Stage IV

Biomarkers: Triple-negative breast cancer; BRCA1 positive

Metastatic Site: Lungs

As of September 2023, April was living with Stage IV metastatic triple-negative breast cancer in the lungs; scans were stable in February but showed growth again in July, and PARP inhibitor therapy was being planned.

The Patient Story
OutcomeSetback / Progression
Megan, who was diagnosed with Stage II Invasive Lobular CarcinomaBreast Cancer

Stage II HR-Positive Invasive Lobular Carcinoma: Megan's Survivor Story

Patient Info: Megan Claire Chase, Female | Stage II

Biomarkers: ER-positive; PR-positive; HER2 not reported

As of July 2023, Megan-Claire was in survivorship after Stage II invasive lobular breast cancer, with clear early scans but significant long-term effects, surgical menopause, chronic pain, fatigue, chemo brain, and inability to tolerate recurrence-prevention medications.

The Patient Story
OutcomeSurvivorship / Completed Treatment
Megan-Claire, who was diagnosed with Stage II Invasive Lobular CarcinomaBreast Cancer

Stage II Invasive Lobular Carcinoma: Megan-Claire's Survivor Story

Patient Info: Megan-Claire, Female, Under 40 | Stage II

As of July 2023, Megan-Claire had completed chemotherapy, breast-conserving surgery with reconstruction/reduction, and 33 radiation rounds, and was living with long-term effects including neuropathy, scarring, fatigue, and radiation trauma; no recurrence or NED status was stated.

The Patient Story
OutcomeSurvivorship / Completed Treatment
Lucinda, who was diagnosed with Invasive Lobular CarcinomaBreast Cancer

Invasive Lobular Carcinoma: Lucinda's Patient Story

Patient Info: Lucinda Rudolph, Female, 60s

As of June 2023, Lucinda was living well after treatment for locally advanced recurrent invasive lobular breast cancer, taking exemestane, receiving supportive care for neuropathy, and returning to MD Anderson every 6 months for checkups.

MD Anderson
OutcomeCare Ongoing
Carol, who was diagnosed with Breast CancerBreast Cancer

BRCA1 Breast Cancer: Carol's Survivor Story

Patient Info: Carol Arnhart

Biomarkers: BRCA1 mutation

She had a complete pathologic response to breast chemotherapy and later reported no evidence of breast cancer.

MD Anderson
OutcomeCancer-Free / NED
Christine, who was diagnosed with Stage III Breast CancerBreast Cancer

Stage III HER2-Positive Breast Cancer: Christine's Survivor Story

Patient Info: Christine Elliott, Female, Under 40 | Stage III

Biomarkers: Estrogen receptor-positive; HER2 and progesterone receptor status not reported

As of May 2023, Christine was about 3 years from diagnosis and in survivorship after chemotherapy, lumpectomy, and radiation. She reported lasting physical and emotional effects but did not state a formal NED status.

YouTube — The Patient Story
OutcomeSurvivorship / Completed Treatment
A patient, who was diagnosed with Breast CancerBreast Cancer

Rare breast blood-vessel cancer (angiosarcoma) in a teenage girl

Patient Info: Anonymized, Female

Biomarkers: Testing for Li-Fraumeni syndrome and POT1 mutation was inconclusive; no inherited cancer predisposition was established

She remained in remission 3 years after diagnosis and continued annual MRI surveillance of the reconstructed and opposite breasts.

PubMed Central
OutcomeCancer-Free / NED